View Exam | PowerPak

1. Which of the following arthritis medication(s) may worsen psoriasis?

A. Gold B. Hydroxychloroquine C. Systemic corticosteroids D. All of the above

2. The vitamin D analogues calcitriol and calcipotriene are indicated by the US Food and Drug Administration for which type of psoriasis?

A. Plaque psoriasis B. Inverse psoriasis C. Pustular psoriasis D. Guttate psoriasis

3. Which of the following is not a common side effect of psoralen plus ultraviolet A light therapy?

A. Photoaging B. Lentigines C. Skin cancers with long-term use D. Tactile sensitivity

4. Clinical studies have suggested that which of the following treatment modalities for psoriasis is linked to the highest adherence rate?

A. Biologics B. Oral systemic therapy C. Phototherapy D. Topical agents

5. Treatment with methotrexate requires monitoring for which of the following toxicities?

A. Bone marrow toxicity B. Liver toxicity C. Lung toxicity D. All of the above

6. Which of the following systemic therapies for psoriasis is (are) in pregnancy category X?

A. Acitretin B. Cyclosporine C. Methotrexate D. A and C

7. Cyclosporine should be limited to what duration of treatment due to the potential for serious side effects?

A. 3 months B. 6 months C. 1 year D. 5 years

8. Ustekinumab is a biologic therapy for psoriasis that offers the ____________.

A. ability to block TNF-α signaling for more than 4 weeks B. option for an intravenous treatment taken every 4 weeks C. efficacy of the TNF-α inhibitor etanercept with more frequent dosing D. efficacy of the TNF-α inhibitor adalimumab with less frequent dosing

9. Phase 2 studies of brodalumab and ixekizumab suggest that patients may experience histologic and clinical responses as soon as _________ after treatment initiation?

A. 2 weeks B. 4 weeks C. 2 months D. 4 months

10. In patients taking infliximab, development of human anti-chimeric antibodies has been linked to which of the following factors?

A. Episodic treatment B. Use of concomitant immunomodulator therapy C. High trough serum levels D. Comorbid cardiovascular disease

11. How often do you NOW PLAN TO educate patients about the efficacy and safety profiles of biologic treatment options?

A. Never B. 25% of the time C. 50% of the time D. 75% of the time E. 100% of the time

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following arthritis medication(s) may worsen psoriasis?

2. The vitamin D analogues calcitriol and calcipotriene are indicated by the US Food and Drug Administration for which type of psoriasis?

3. Which of the following is not a common side effect of psoralen plus ultraviolet A light therapy?

4. Clinical studies have suggested that which of the following treatment modalities for psoriasis is linked to the highest adherence rate?

5. Treatment with methotrexate requires monitoring for which of the following toxicities?

6. Which of the following systemic therapies for psoriasis is (are) in pregnancy category X?

7. Cyclosporine should be limited to what duration of treatment due to the potential for serious side effects?

8. Ustekinumab is a biologic therapy for psoriasis that offers the ____________.

9. Phase 2 studies of brodalumab and ixekizumab suggest that patients may experience histologic and clinical responses as soon as _________ after treatment initiation?

10. In patients taking infliximab, development of human anti-chimeric antibodies has been linked to which of the following factors?

11. How often do you NOW PLAN TO educate patients about the efficacy and safety profiles of biologic treatment options?

« Return to Activity

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following arthritis medication(s) may worsen psoriasis?

2. The vitamin D analogues calcitriol and calcipotriene are indicated by the US Food and Drug Administration for which type of psoriasis?

3. Which of the following is not a common side effect of psoralen plus ultraviolet A light therapy?

4. Clinical studies have suggested that which of the following treatment modalities for psoriasis is linked to the highest adherence rate?

5. Treatment with methotrexate requires monitoring for which of the following toxicities?

6. Which of the following systemic therapies for psoriasis is (are) in pregnancy category X?

7. Cyclosporine should be limited to what duration of treatment due to the potential for serious side effects?

8. Ustekinumab is a biologic therapy for psoriasis that offers the ____________.

9. Phase 2 studies of brodalumab and ixekizumab suggest that patients may experience histologic and clinical responses as soon as _________ after treatment initiation?

10. In patients taking infliximab, development of human anti-chimeric antibodies has been linked to which of the following factors?

11. How often do you NOW PLAN TO educate patients about the efficacy and safety profiles of biologic treatment options?

« Return to Activity

Customers who Purchased
this Activity also Purchased